The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with post-traumatic stress disorder (PTSD) ...

INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday. The company will present findings from ...

T is a Novel, Non-Aromatizing Androgen, Offering the Benefits of Testosterone Without Converting to Estradiol Addressing a ...

IOVA's ASCO update reiterates the value of Amtagvi in melanoma, but upcoming data in lung cancer and endometrial cancer in H2 ...

Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss PR Newswire DURHAM, N.C. and BEIJING ...

A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...

G RI Bio has announced encouraging six-week interim safety outcomes from the ongoing Phase IIa trial of the small molecule ...

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress Provided by GlobeNewswire Jun 11, 2025, 10 ...

At this year’s BIO International Convention, held June 16 – 19 in Boston, MA, two companies, 64x Bio and Fauna Bio, introduced new products aimed at improving therapy delivery and identifying ...